Advancing Health Economics and Regulatory Analytics Across the Midwest Bioscience Corridor
For most early-stage medtech companies, real world evidence is something they hear about long before they can afford to use it.
In the latest episode of Favorable Environments, host Tung Nguyen connected with Ian Weimer, founder of Weimer Analytics, for a wide-ranging discussion on real world evidence (RWE), the evolving FDA landscape, and why data-driven insights are becoming essential infrastructure for early-stage medtech and biotech companies. Their conversation grew out of the USD Discovery District’s sponsorship of the 2025 Medical Alley Summit—an example of the regional collaboration that turns vision into momentum.
Weimer Analytics, launched in 2025 and based in Minnesota’s Twin Cities, delivers health economics, real world evidence, and regulatory analytics solutions to clients ranging from Fortune 500 pharmaceutical and medical device leaders to emerging startups. With more than eight years of experience, including three years leading analytics projects at a boutique healthcare consultancy that contributed to 16 peer-reviewed publications and regulatory submissions, Ian brings deep expertise in turning messy, real-world data into clear value stories.
The Unmet Need: Real World Evidence for Small and Medium-Sized Innovators
Ian saw a clear gap. “I think I saw an unmet need for small to medium sized companies in accessing these services,” he shared. While large pharma has long invested in real world evidence, many earlier-stage medtech and biotech firms struggle to access the same rigorous, tailored insights—especially when developing novel products for novel conditions.
That’s where burden-of-disease studies and other real world evidence approaches shine. By working with clinical and economic data drawn from real-world patient experiences, companies can start to understand the problem they’re trying to solve before a product is fully built. “It can kind of give an estimate on what the value could be before the product is even developed,” Ian noted—powerful ammunition for investor conversations, FDA meetings, and eventual reimbursement discussions with payers.
A Shifting Regulatory Landscape Opens Doors
December 2025 marked a pivotal moment: the FDA released updated guidance that is far more accepting of real world evidence for initial approvals. Previously reliant on identifiable patient records, the agency now evaluates de-identified datasets on a case-by-case basis. With more than 250 approvals incorporating real world evidence since 2016, Ian expects this acceleration to continue.
This evolution benefits startups in particular. Pre-approval, real world evidence helps build the evidence package and de-risk investment. Post-approval, it supports marketing, market access, and ongoing label expansions. “They’re increasingly being accepted in the pre-approval stage,” Ian explained, showcasing how real world evidence is moving from nice-to-have to must-have infrastructure for commercialization.
Data Realities: Messy but Invaluable
One common misconception Ian encounters is that real-world datasets are clean and plug-and-play. “Electronic health record data is one of the main sources, and it can be quite messy,” he said with a smile. Extreme values, inconsistent nomenclature, and the inherent variability of clinical practice all require careful cleaning and statistical rigor. Yet that very messiness is the source of its power: unlike tightly controlled clinical trials, real world evidence reflects how interventions perform in everyday settings across diverse patient populations.
Most of the data Ian works with is U.S.-focused (with some international sources available), and all partnerships operate under strict HIPAA-compliant contracts and data-use agreements. He emphasizes ongoing training, secure handling practices, and—especially with emerging AI tools—thoughtful data governance. “Being mindful of that and any other tools… every company should have data governance in mind,” he advised.
AI as a Safe Multiplier for Smaller Firms
As a solo founder scaling a services business, Ian is pragmatic about AI adoption. Tasks that once took months now take hours or days when applied responsibly. He uses tools like Claude (with enterprise versions that retain no data) and stays vigilant about retention policies and settings. The goal: amplify what a small firm can deliver without compromising the integrity or privacy that clients—and ultimately patients—demand.
Building the Ecosystem, One Connection at a Time
Ian is deeply embedded in Minnesota’s medtech corridor—Medtronic, Boston Scientific, emerging startups, Mayo Clinic events, and the broader Medical Alley network. He attends 8–10 networking events a month and actively shares insights on LinkedIn. Yet he sees the same challenges—and opportunities—across the upper Midwest: funding remains tight for early-stage companies, but lower operating costs, tight networks, and a collaborative culture create a favorable environment for sustainable growth.
The USD Discovery District’s role in facilitating his conversation with Tung is a living example of that cross-border infrastructure. By sponsoring events that bring together founders, investors, and service providers, the USD Discovery District is helping knit together the talent pipeline, applied research capacity, and commercialization pathways that define South Dakota’s 36-year overnight success story.
Looking Ahead: Awareness, Partnerships, and Purpose-Built Growth
Ian’s near-term focus is spreading awareness of how real world evidence can support companies at every stage—especially those that traditionally lacked access. He’s actively building clinical and data partnerships locally, regionally, and potentially nationally. Longer term, he’s exploring a clinical machine-learning product that could integrate with remote patient monitoring or surgical settings to predict clinical events—always grounded in unmet need and rigorous validation.
“I want to continue to implement AI in a safe way,” he said, “As a smaller firm, that’s a real multiplier.”
Listen to the Full Conversation
Ian Weimer’s journey—from first-generation entrepreneur and data scientist to founder of a purpose-built analytics firm—embodies the grounded optimism and collaborative spirit that define the Midwest bioscience ecosystem. His work on real world evidence is exactly the kind of applied research and commercialization infrastructure that turns scientific possibility into patient impact.
Listen to Episode 18 of Favorable Environments on Apple Podcasts, Spotify, YouTube, or at favorableenvironments.com.
Learn more about Weimer Analytics at weimeranalytics.com.
Explore opportunities at the USD Discovery District—customizable lab and office space in Building 1, university partnerships, postdoctoral talent, and a growing community of biotech leaders. Schedule a tour today.
For companies trying to make sense of complex data, or trying to prove the value of something new, that kind of infrastructure matters.
The work is still early. But it’s becoming easier to see where it’s going.